The peptide bioregulators are a group before they are individual compounds, and reading any one of them without that context makes the naming look arbitrary and the literature look thinner than it is.
They come from a Soviet-era research programme begun in the 1970s, associated principally with Vladimir Khavinson and the St Petersburg Institute of Bioregulation and Gerontology. The programme's organising idea was that very short peptide fragments — two to four residues — isolated from or modelled on specific tissues could act as regulatory signals associated with those tissues.
What the group has in common
- They are very short. Two to four residues, against the twenty to forty of most research peptides. Epithalon is a tetrapeptide — with a telomerase literature that needs careful reading; Thymalin is a preparation rather than a single defined sequence — which changes what its certificate can say.
- They are named after tissues, not sequences. Pinealon for the pineal gland, Prostamax for prostate tissue, Testagen for testicular tissue. This is programme nomenclature, not systematic chemistry, which is why the names do not resemble anything else in peptide chemistry.
- Their literature is largely Russian-language. A substantial part of the primary work appeared in journals with limited international indexing, some of it decades ago. That is a real obstacle to evaluation rather than a criticism of the work.
- Short peptides behave differently in solution. Fewer residues means less secondary structure to lose, which changes the degradation profile relative to longer sequences.
The catalogue's members, with the sequence each name stands for:
| Name | Sequence | Residues | Tissue the name refers to |
|---|---|---|---|
| Vilon | Lys-Glu | 2 | Thymus |
| Vesugen | Lys-Glu-Asp | 3 | Vascular |
| Pinealon | Glu-Asp-Arg | 3 | Brain / pineal |
| Epithalon | Ala-Glu-Asp-Gly | 4 | Pineal |
| Prostamax | Lys-Glu-Asp-Pro | 4 | Prostate |
| Testagen | Lys-Glu-Asp-Gly | 4 | Testis |
| Thymalin | Extract-derived; not one defined sequence | — | Thymus |
Two things are visible at once. The sequences overlap heavily — Lys-Glu-Asp appears in four of them — so the tissue names imply a specificity the chemistry does not obviously support. And every one is short enough that the usual questions about structure do not apply: there is no fold to lose, and no receptor has been established for any of them.
How to read the evidence honestly
Why is this literature harder to evaluate than most?
Three reasons, none of which is that the work does not exist. Much of it is not indexed in the databases most researchers search, so a standard literature review under-represents it. Much of it is in Russian, and translation quality varies. And a proportion of the frequently cited results come from the same institutional group, which is common in a field founded by one programme but means independent replication is thinner than citation counts suggest.
The appropriate posture is neither dismissal nor acceptance. It is to read what exists, note where replication is independent and where it is not, and be explicit about that distinction in any write-up.
What does the tissue name actually tell you?
Less than it appears to. A name like Prostamax reflects the tissue the programme associated the compound with, not a demonstrated tissue-specific mechanism in the sense a receptor pharmacologist would mean. Treating the name as a mechanistic claim is the most common error in reading this group.
Does a short sequence mean a simple molecule?
Simple to synthesise and characterise, yes — a tetrapeptide is straightforward to confirm by mass spectrometry and to resolve chromatographically. Simple in behaviour, not necessarily. Short peptides can be conformationally flexible, and very short sequences are more susceptible to exopeptidase attack from both termini because there is less molecule between the ends.
How should these be handled relative to longer peptides?
The same fundamentals apply — the degradation routes do not change with length — but two things shift. Short, polar sequences tend to be more freely soluble in aqueous buffer than long hydrophobic ones, which removes one common problem. And because they are small, the same mass is a much larger number of molecules, so a mg/mL figure translates to a far higher molar concentration than intuition from larger peptides suggests. The conversion is worth doing explicitly.
Where they sit in a catalogue
They are a coherent group with a shared origin, not a set of unrelated compounds that happen to be short. Studying one without reading the programme context is possible but leaves the naming, the literature pattern and the compound relationships unexplained. Studying the group means accepting that the evidence base has a different shape from, say, the GLP-1 class — older, more concentrated in one research tradition, and less independently replicated. The same reading discipline applies to DSIP and to Selank and Semax, which come from the same tradition and carry the same evaluation problem.
That is a reason to read carefully. It is not a reason to pretend the literature is either stronger or weaker than it is.
What a write-up should record for this group in particular
Everything you would record for any peptide — compound, lot, supplier, purity, net peptide content, diluent, concentration — plus two things specific to this literature.
The exact sequence. Because these compounds are named after tissues rather than structures, the name alone does not identify the molecule to a reader outside the field. Stating the residues removes the ambiguity in one line.
Which literature the rationale came from. If the basis for studying a compound is work published in a journal with limited international indexing, saying so is not a weakness in the write-up — it is the information a reader needs to weigh it. Omitting it invites the reader to assume a depth of independent replication that may not exist.
Are these compounds analytically straightforward?
Generally yes, and it is one of the few things easier about them. A two- to four-residue peptide gives a clean mass spectrum with an unambiguous molecular ion, and resolves well by reversed-phase chromatography. Identity confirmation is therefore rarely the uncertain part — which puts the weight of any doubt on the biology rather than on whether the vial contains what the label says. Certificates for every lot are searchable on the COA verification page.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
